Wanbury Ltd

₹ 262 1.61%

05 Jun - close price

About

Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research^[1]

Key Points

Business Overview:^[1]
WL is a pharmaceutical company with a presence in the API global market and domestic branded Formulation. It’s majorly into Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India
Formulation presence.

Website BSE NSE

Market Cap ₹ 916 Cr.
Current Price ₹ 262
High / Low ₹ 329 / 162
Stock P/E 13.2
Book Value ₹ 41.3
Dividend Yield 0.00 %
ROCE 30.8 %
ROE 68.4 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company has delivered good profit growth of 47.8% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 82.6%

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 10.6% over past five years.
Tax rate seems low
Promoters have pledged 62.2% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	133	146	144	146	139	131	161	133	172	163	160	162	165
	119	133	127	124	121	120	141	120	142	139	134	136	135
Operating Profit	14	13	17	21	18	11	20	14	30	24	26	27	30
OPM %	11%	9%	12%	15%	13%	8%	12%	10%	17%	15%	16%	16%	18%
	-3	1	1	1	1	1	2	1	2	0	0	0	-3
Interest	8	6	8	8	7	8	10	10	9	8	7	7	8
Depreciation	3	3	3	3	3	3	3	3	3	4	4	4	3
Profit before tax	1	5	7	10	8	1	8	1	19	14	15	16	15
Tax %	-11%	6%	-2%	-0%	3%	0%	2%	5%	-6%	1%	-0%	1%	-43%
	1	5	7	10	8	1	8	1	20	13	15	16	22
EPS in Rs	0.31	1.43	2.25	3.14	2.47	0.32	2.45	0.37	6.18	4.10	4.35	4.52	6.21
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015 6m	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	250	420	432	370	391	367	392	511	500	578	600	650
	228	387	414	438	375	344	374	475	476	506	523	544
Operating Profit	21	34	19	-68	16	23	18	36	23	72	77	107
OPM %	9%	8%	4%	-18%	4%	6%	5%	7%	5%	12%	13%	16%
	6	0	90	76	9	84	2	77	0	1	3	-3
Interest	19	32	36	31	40	33	23	21	21	29	37	30
Depreciation	5	9	10	10	10	10	10	11	12	13	13	14
Profit before tax	4	-7	62	-32	-25	65	-12	81	-10	31	30	60
Tax %	28%	0%	1%	-1%	-1%	0%	2%	-0%	1%	1%	-3%	-11%
	3	-7	62	-32	-25	64	-13	81	-10	30	31	66
EPS in Rs	1.61	-3.52	26.71	-13.49	-10.48	25.79	-5.04	24.94	-3.18	9.28	9.32	18.93
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	4%
5 Years:	11%
3 Years:	9%
TTM:	8%

Compounded Profit Growth
10 Years:	30%
5 Years:	48%
3 Years:	107%
TTM:	139%

Stock Price CAGR
10 Years:	20%
5 Years:	21%
3 Years:	66%
1 Year:	-11%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	83%
Last Year:	68%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	20	20	23	24	24	25	25	33	33	33	33	35
Reserves	-188	-183	-151	-183	-207	-143	-156	-30	-40	-5	26	110
	381	373	273	224	233	164	166	74	68	116	179	224
	182	176	265	207	235	231	253	275	241	199	176	149
Total Liabilities	394	386	411	271	285	277	288	351	302	343	414	518
	164	180	186	178	172	164	167	167	167	167	201	229
CWIP	19	14	10	10	9	14	11	2	2	3	5	25
Investments	0	0	0	0	0	0	0	0	0	0	0	0
	212	192	215	83	103	99	109	182	133	173	208	263
Total Assets	394	386	411	271	285	277	288	351	302	343	414	518

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	40	43	43	32	30	44	17	41	20	5	26	32
	-5	-20	-13	-1	-3	64	8	1	-9	-17	-51	-56
	-30	-28	-27	-33	-27	-108	-17	-29	-32	14	26	22
Net Cash Flow	5	-5	3	-2	-0	-0	7	13	-21	2	1	-2
Free Cash Flow	35	22	29	30	25	36	12	42	7	-9	-23	-28
CFO/OP	187%	129%	234%	-49%	188%	188%	97%	113%	86%	7%	35%	30%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	144	65	71	29	41	50	32	45	50	56	70	80
Inventory Days	103	69	63	27	36	25	41	60	26	43	47	67
Days Payable	300	171	259	173	208	252	220	218	178	196	172	142
Cash Conversion Cycle	-54	-37	-124	-117	-131	-176	-147	-112	-101	-96	-55	6
Working Capital Days	-139	-123	-164	-251	-230	-211	-227	-134	-129	-37	4	17
ROCE %		12%	55%	-1%	26%	31%	23%	46%	17%	58%	34%	31%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Total Employee Strength
Number

x,xxx	xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx
xx	xx	xx	xx		xx	xx	xx	xx	xx	xx
						xxx	xxx	xxx	xxx	xxx
									x	xx
										xx
										xx
										xx
										xx
										xx
										xxx
										x,xxx
										xx
										x,xxx

Please log in to see hidden values.

Global Market Share - Metformin
%

Cumulative Installed Reactor Capacity
KL

Active API Products
Number

API Sales Volume Growth - Diphenhydramine
%

API Sales Volume Growth - Sertraline
%

API Sales Volume Growth - Tramadol
%

Global Market Share - Sertraline
%

Global Market Share - Tramadol
%

Medical Representatives / Field Force
Number

Metformin Production Capacity
TPA

Number of Countries Exported To
Number

Number of Distributors
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	39.84%	39.80%	39.79%	39.79%	39.79%	39.77%	39.76%	39.76%	39.63%	43.09%	43.08%	43.01%
	0.00%	0.00%	0.00%	0.18%	0.22%	1.02%	0.84%	1.55%	1.59%	0.82%	0.72%	0.59%
	60.16%	60.19%	60.20%	60.02%	59.97%	59.21%	59.40%	58.68%	58.79%	56.08%	56.21%	56.39%
No. of Shareholders	11,741	11,634	11,616	13,087	14,400	17,199	17,999	17,889	17,894	17,717	17,261	16,732

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	56.11%	54.93%	54.93%	52.13%	52.09%	39.89%	39.84%	39.79%	39.76%	43.01%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.18%	1.55%	0.59%
	2.43%	2.26%	2.26%	2.14%	1.13%	0.00%	0.00%	0.00%	0.00%	0.00%
	41.46%	42.81%	42.81%	45.73%	46.78%	60.11%	60.16%	60.02%	58.68%	56.39%
No. of Shareholders	17,556	17,088	12,831	12,494	11,831	11,289	11,911	13,087	17,889	16,732

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Wanbury Ltd

Wanbury Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls